Fidaxomicin in Clostridium difficile infection: Latest evidence and clinical guidance

Therapeutic Advances in Chronic Disease

Volumn 5, Issue 2, 2014, Pages 69-84

  Mullane, Kathleen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Clostridium difficile associated diarrhea (CDAD); Clostridium difficile infection (CDI); Fidaxomicin; Metronidazole; Vancomycin

Indexed keywords

BACITRACIN; CADAZOLID; FIDAXOMICIN; FUSIDIC ACID; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; RAMOPLANIN; RIFAXIMIN; TEICOPLANIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; VP 20621;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE INFECTION; COMPARATIVE MOLECULAR FIELD ANALYSIS; DIARRHEA; DRUG MEGADOSE; DRUG TOLERABILITY; EPIGASTRIC PAIN; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTESTINE FLORA; INTESTINE OBSTRUCTION; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NONHUMAN; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TASTE DISORDER;

EID: 84898875472     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622313511285     Document Type: Review

References (104)

1. Al-Nassir W. Sethi A. Li Y. Pultz M. Riggs M. Donskey C. (2008) Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 52: 2403–2406.
2. Artsimovitch I. Seddon J. Sears P. (2012) Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis 55(Suppl. 2): S127–S131.
3. Aslam S. Hamill R. Musher D. (2005) Treatment of Clostridium difficile associated disease: old therapies and new strategies. Lancet Infect Dis 5: 549–557.
4. Avbersek J. Janezic S. Pate M. Rupnik M. Zidaric V. Logar K. et al. (2009) Diversity of Clostridium difficile in pigs and other animals in Slovenia. Anaerobe 15: 252–255.
5. Babakhani F. Bouillant L. Gomez A. Sears P. Nguyen L. Sonenshein A. (2012) Fidaxomicin inhibits spore production in Clostridium difficile. Clin Inf Dis 55(Suppl. 2): S162–S169.
6. Babakhani F. Bouillaut L. Sears P. Sims C. Gomez A. Sonenshein A. (2013) Fidaxomicin inhibits toxin production in Clostridium difficile. J Antimicrob Chemother 68: 515–522.
7. Babakhani F. Gomez A. Robert N. Sears P. (2011) Postantibiotic effect of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. Antimicrob Agents and Chemother 55: 4427–4429.
8. Baines S. O'Connor R. Freeman J. Fawley W. Harmanus C. Mastriantonio P. et al. (2008) Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62: 1046–1052.
9. Bakri M. Brown D. Butcher J. Sutherland A. (2009) Clostridium difficile in ready-to-eat salads, Scotland. Emerg Infect Dis 15: 817–818.
10. Barbut F. Mastrantonio P. Delmee M. Brazier J. Kuijper E. Poxton I. et al. (2007) Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterization of the isolates. Clin Microbiol Infect 13: 1048–1057.
11. Bauer M. Kuijper E. van Dissel J. (2009) European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infec 15: 1067–1079.
12. Biedenbach D. Ross J. Putnam S. Jones R. (2010) In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp. Antimicrob Agents Chemother 54: 2273–2275.
13. Bolton R. Culshaw M. (1986) Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 27: 1169–1172.
14. Bouttier S. Barc M. Felix B. Lambert S. Collignon A. (2010) Clostridium difficile in ground meat, France. Emerg Infect Dis 16: 733–735.
15. Bouza E. (2012) Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect 18(Suppl. 6): 5–12.
16. Centers for Disease Control and Prevention (1995) Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HIC-PAC). Am J Infect Control 23: 87–94.
17. Centers for Disease Control and Prevention (2005) Severe Clostridium difficile-associated disease in populations previously at low risk–four states, 2005. MMWR Morb Mortal Wkly Rep 54: 1201–1205.
18. Cohen S. Gerding D. Johnson S. Kelly C. Loo V. McDonald L. et al. (2010) Clinical practice guidelines for Clostridium difficile infection in Adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 31: 431–455.
19. Cornely O. (2012) Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin? Clin Microbiol Infect 18(Suppl. 6): 28–35.
20. Cornely O. Crook D. Esposito R. Poirer A. Somero M. Weiss K. (2012 a) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada and the USA: a double-blinded, non inferiority, randomised controlled trial. Lancet Infec Dis 12: 281–289.
21. Cornely O. Miller M. Fantin B. Mullane K. Kean Y. Gorbach S. (2013) Resolution of Clostridium difficile –associated diarrhea in cancer patients treated with fidaxomicin or vancomycin. J Clin Oncol 31: 2493–2499.
22. Cornely O. Miller M. Louie T. Crook D. Gorbach S. (2012 b) Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 55(Suppl. 2): S154–S161.
23. Coronelli C. White R. Lancini G. Parenti F. (1975) A new antibiotic from actinoplanes; II. Isolation, chemical, biological and biochemical characterization. J Antibiot (Tokyo) 28: 253–259.
24. Crook D. Walker A. Kean Y. Weiss K. Cornely O. Miller M. et al. (2012) Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials. Clin Infect Dis 55(Suppl. 2): S93–S103.
25. Elixhauser A. Steiner C. Gould C. (2012) Readmissions following hospitalizations with Clostridium difficile infections, 2009. HCUP Statistical Brief #145, Agency for Healthcare Research and Quality, Rockville, MD, December 2012. Available at http://www.hcup-us.ahrq.gov/reports/statbriefs/sb145.pdf.
26. Eyre D. Walker A. Wyllie D. Dingle K. Griffiths D. Finney J. et al. (2012) Predictors of first recurrence of Clostridium difficile infection: implications for initial management. Clin Infect Dis 55(Suppl. 2): S77–S87.
27. Fellmeth G. Yarlagadda S. Iyer S. (2010) Epidemiology of community-onset Clostridium difficile infection in a community in the South of England. J Infect Public Health 3: 118–123.
28. Freeman J. Bauer M. Baines S. Corver J. Fawley W. Goorhuis B. et al. (2010) The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23: 529–549.
29. Garey K. Sethi S. Yadav Y. DuPont H. (2008) Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 70: 298–304.
30. George W. Rolfe R. Finegold S. (1982) Clostridium difficile and its cytotoxin in feces of patients with antimicrobial agent-associated diarrhea and miscellaneous conditions. J Clin Microbiol 15: 1049–1053.
31. Ghantoji S. Sail K. Lairson D. DuPont H. Garey K. (2010) Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 74: 309–318.
32. Goldstein E. Citron D. Sears P. Babakhani F. Sambol S. Gerding D. (2011) Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 55: 5194–5199.
33. Goorhuis A. Debast S. van Leengoed L. Harmanus C. Notermans D. Bergwerff A. et al. (2008) Clostridium difficile PCR ribotype 078: an emerging strain in humans and in pigs? J Clin Microbiol 46: 1157–1158.
34. Gough E. Shaikh H. Manges A. (2011) Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 53: 994–1002.
35. Hebert C. Hongyan D. Peterson L. Robicsek A. (2013) Electronic health record-based detection of risk factors for Clostridium difficile infection. Infect Cont Hospital Epidemiol 34: 407–414.
36. Hecht D. Galang M. Sambol S. Osmolski J. Johnson S. Gerding D. (2010) In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Ag Chemother 51: 2716–2719.
37. Hempil S. Newberry S.J. Maher A.R. Wang Z. Miles J.V. Shannon R. Johnson B. Shekille P.G. (2012) Probiotics for the prevention and treatment of antibiotic associated diarrhea. JAMA 307 (18): 1959–1969.
38. Hensgens M. Goorhuis A. Dekkers O. Kuijper E. (2012 a) Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicr Chemother 67: 742–748.
39. Hensgens M. Keessen E. Squire M. Riley T. Koene M. de Boer E. et al. (2012 b) Clostridium difficile infection in the community: a zoonotic disease? Clin Microbiol Infect 18: 635–645.
40. Hu M. Katchar K. Kyne L. Maroo S. Tummala S. Dreisbach V. et al. (2009) Prospective Derivation and Validation of a Clinical prediction Rule for recurrent Clostridium difficile Infection. Gastroenterol 136: 1206–1214.
41. Huebner E. Surawicz C. (2006) Treatment of recurrent Clostridium difficile diarrhea. Gastroenterol Hepatol 2: 203–208.
42. Jernberg C. Lofmark S. Edlund C. Jansson J. (2010) Long-term impacts of antibiotic exposure on the human intestinal microbiota. Microbiology 15: 3216–3223.
43. Johnson A. (2007) Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Investig Drugs 8: 168–173.
44. Johnson S. Homann S.R. Bettin K.M. Quick J.N. Clabots C.R. Peterson L.R. et al. (1992) Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with Vancomycin or Metronidazole: a randomized, placebo-controlled trial. Ann Intern Med 117 (4): 297–302.
45. Johnson B.C. Ma S.S.Y. Goldberg J.Z. Thorlund K. Vandvik P.O. Loeb M. et al. (2012) Probiotics for the prevention of Clostridium adifficile associated diarrhea: A systematic review and meta analysis. Ann Intern Med 157 (12): 878–888.
46. Keel K. Brazier J. Post K. Weese S. Songer J. (2007) Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J Clin Microbiol 45: 1963–1964.
47. Kelly C. LaMont J. (1998) Clostridium difficile infection. Annu Rev Med 49: 375–390.
48. Kelly C. Pothoulakis C. LaMont J. (1994) Clostridium difficile colitis. N Engl J Med 330: 257–262.
49. Khanna S. Pardi D. (2010) The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Expert Rev Gastroenterol Hepatol 4: 409–416.
50. Khanna S. Pardi D. Aronson S. Kamer P. Baddour L. (2012 a) Outcomes in community-acquired Clostridium difficile infection. Aliment Pharmacol Ther 35: 613–618.
51. Khanna S. Pardi D. Aronson S. Kammer P. Orenstein R. St Sauver J. et al. (2012 b) The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 107: 89–95.
52. Kutty P. Woods C. Sena A. Benoit S. Naggie S. Frederick J. et al. (2010) Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA. Emerg Infect Dis 16: 197–204.
53. Lambert P. Dyck M. Thompson L. Hammond G. (2009) Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol 30: 945–951.
54. Lavergne V. Beausejour Y. Pichette G. Ghannoum M. Hann S. (2013) Lymphopenia as a novel marker of Clostridium difficile infection recurrence. J Infect 66: 129–135.
55. Lessa F. Gould C. McDonald L. (2012) Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 55(Suppl. 2): S65–S70.
56. Loo V. Poirier L. Miller M. Oughton M. Libman M. Michaud S. et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353: 2442–2449.
57. Louie T. Cannon K. Byrne B. Emery J. Ward L. Eyben M. et al. (2012) Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin re-expression and recurrence of CDI. Clin Infect Dis 55(Suppl. 2): S132–S142.
58. Louie T. Gerson M. Grimard D. Johnson S. Poirier A. Weiss K. et al. (2007) Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile associated diarrhea (CDAD). Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 17–20 September 2007; Abstract K-425a.
59. Louie T. Miller M. Crook D. Lentnek A. Bernard L. High K. et al. (2013) Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 61: 222–230.
60. Louie T. Miller M. Mullane K. Weiss K. Lentnek A. Golan Y. et al. (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364: 422–431.
61. Mascio C.T.M. Mortin L.I. Howland K.T. van Praagh A.D.G. Zhang S. Arya A. Chuong C.L. Kang C. Li T. Silverman J.A. (2012) In-vitro and in-vivo characterization of CB 183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicr Ag Chemother 55 (10): 5023–5030.
62. Mauskopf J. Paus J. Grant D. Stergachis A. (1998) The role of cost-consequence analysis in healthcare decision-making. Pharmaco Economics 13: 277–288.
63. McDonald L. Killgore G. Thompson A. Owens R. Kazakova S. Sambol S. et al. (2005) An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353: 2433–2441.
64. McFarland L.V. (2006) Meta analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroent 101: 812–822.
65. McFarland L. Elmer G. Surawicz C. (2002) Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97: 1769–1775.
66. McFarland L. Mulligan M. Kwok R. Stamm W. (1989) Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 320: 204–210.
67. McFarland L. Surawicz C. Greenberg R. Fekety R. Elmer G. Moyer K. et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271: 1913–1918.
68. McGlone S. Balley R. Zimmer S. Popovick M. Tian Y. Ufberg P. et al. (2012) The economic burden of Clostridium difficile. Clin Microbiol Infect 18: 282–289.
69. Metcalf D. Costa M. Dew W. Weese J. (2010) Clostridium difficile in vegetables, Canada. Lett Appl Microbiol 51: 600–602.
70. Miller B. Chen L. Sexton D. Anderson D. (2011) Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 32: 387–390.
71. Miller M. Mullane K. Weiss K. Lentnek A. Golan Y. Sears P. et al. (2009) Faster time to resolution of diarrhea with fidaxomicin vs. vancyomycin in patients with Clostridium difficile infection (CDI). In 47th Annual Infectious Diseases Society of America Meeting, Philadelphia, PA, 29 October–1 November 2009.
72. Minino A. Xu J. Kochanek K. (2010) Deaths: preliminary data for 2008. National Vital Statistics Report 59. Hyattsville, MD: National Center for Health Statistics. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_02.pdf.
73. Mullane K. Golan Y. Crook D. Cornely O. Miller M. Louie T. et al. (2013) Renal impairment and response to fidaxomicin versus vancomycin in patients with Clostridium difficile infection. Am J Nephrol 38: 1–11.
74. Mullane K. Gorbach S. (2011) Fidaxomicin: first-in-class macrocyclic antibiotic. Exp Rev Anti Infec Ther 9: 767–777.
75. Mullane K. Miller M. Weiss K. Lentnek A. Golan Y. Sears P. et al. (2011) Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 53: 440–447.
76. Nerandzic M. Mullane K. Miller M. Fabakhani F. Donskey C. (2012) Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida spp. in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 55(Suppl. 2): S121–S126.
77. Optimer Pharmaceuticals Inc. (2011) DIFICID® Prescribing Information. Data on File. Clinical Study Report OPT-80–004 Final, June 4, 2010 and Clinical Study Report OPT-80–003 Final, June 17, 2010 (Version 2). San Diego, CA: Optimer Pharmaceuticals, Inc.
78. Parenti F. Pagani H. Beretta G. (1975) Lipiarmycin, a new antibiotic from actinoplanes. I. Description of the producer strain and fermentation studies. J Antibiotics (Tokyo) 28: 247–252.
79. Pepin J. Alary M. Valiquette L. Raiche E. Ruel J. Fulop K. et al. (2005) Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40: 1591–1597.
80. Pepin J. Valiquette L. Alary M. Villemure P. Pelletier A. Forget K. et al. (2004) Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171: 466–472.
81. Rafii F. Sutherland J. Cerniglia C. (2008) Effects of treatment with antimicrobial agents on the human colonic microflora. Ther Clin Risk Manag 4: 1343–1357.
82. Rege S. Patino H. Bernardo P. Lee C. Mullane K. Vetticaden S. et al. (2012) Impact of risk factors on recurrence of CDI: Comparison between CB-183,315 and oral vancomycin. In European Congress of Clinical Microbiology and Infectious Diseases, London, 31 March–3 April.
83. Rupnik M. Widmer A. Zimmermann O. Eckert C. Barbut F. (2008) Clostridium difficile toxinotype V, ribotype 078, in animals and humans. J Clin Microbiol 46: 2146.
84. Rupnik M. Wilcox M. Gerding D. (2009) Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 7: 526–536.
85. Sclar D. Robison L. Oganov A. Schmidt J. Bowen K. Castillo L. (2012) Fidaxomicin for Clostridium difficile-associated diarrhoea; epidemiological method for estimation of warranted price. Clin Drug investing 32: e17–e24.
86. Shaughnessy M. Micielli R. Depestel D. Arndt J. Strachan C. Welch K. et al. (2011) Evaluation of hospital room assignment and acquisition of Clostridium difficile infection. Infect Control Hosp Epidemiol 32: 201–206.
87. Sears P. Babakhani F. Citron D. (2008) Typing and susceptibility of bacterial isolates from the OPT-80 (PAR-101) phase 2A study for C. difficile-associated diarrhea. Poster at the 9th Biennial Congress of the Anaerobe Society of the Americas, Long Beach, CA.
88. Sears P. Crook D. Louie T. Miller M. Weiss K. (2012) Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with clostridium difficile infection. Clin Infect Dis 55(Suppl. 2): S116e20.
89. Sears P. Louie T. Mullane K. Miller M. (2009) Pharmacokinetics / pharmacodynamics (PK/PD) of fidaxomicin in treatment of Clostridium difficile infection (CDI). In 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 12–15 September, San Francisco, CA.
90. Seddon J. Sears P. (2003) Preliminary OPT-80 Mode of Action Studies. Report Number BIO090203A, Optimer Pharmaceuticals, Inc., San Diego, CA.
91. Sergio S. Pirali G. White R. Parenti F. (1975) Lipiamycin, a new antibiotic from actinoplanes; III. Mechanism of action. J Antibiotics (Tokyo) 38: 543–549.
92. Shue Y. Sears P. Shangle S. Walsh R. Lee C. Gorbach S. et al. (2008) Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 52: 1391–1395.
93. Surawicz C. Brandt L. Binion D. Ananthakrishnan A. Curry S. Gilligan P. et al. (2013) Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108: 478–498.
94. Srivastava A. Talaue M. Liu S. Degan D. Ebright R. Sineva E. et al. (2011) New target for inhibition of bacterial RNA polymerase: ‘switch region’. Curr Opin Microbiol 14: 532–543.
95. Steiner C. Barrett M. Terrel L. (2012) HCUP Projections: Clostridium difficile Hospitalizations 2011 to 2012. 2012. HCUP Projections Report # 2012–01. US Agency for Health-care Research and Quality. Available at: http://www.hcup-us.ahrq.gov/reports/projections/2012–01.pdf and http://www.hcup-us.ahqr.gov/reports/statbriefs/sb145(12/11/2012).
96. Stranges P. Hutton D. Collins C. (2013) Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value in Health, in press.
97. Tannock G. Munro K. Taylor C. Lawley B. Young W. Byrne B. et al. (2010) New macrocycle antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 156: 3354–3359.
98. Theriault R. Karwowski J. Jackson M. Girolami R. Sunga G. Vojtki C. et al. (1987) Tiacumicins, a novel complex of 18-membered macrolide antibiotics. J Antibiot 40: 567–574.
99. van Nood E. Vrieze A. Nieuwdorp M. Fuentes S. Zoetendal E. de Vos W. et al. (2013) Duodenal infusion of Donor Feces for Recurrent Clostridium difficile. New Engl J Med 368: 407–415.
100. Venugopal A. Johnson S. (2012) Current state of Clostridium difficile treatment options. Clin Infect Dis 55(Suppl. 2): S71–S76.
101. Wiegand P.N. Nathwani D. Wilcox M.H. Stephens J. Shelbaya A. Haider S. (2012) Clinical and economic burden of Clostridium difficile infection in Europe: A systematic review of health care facility acquired infection. J Hosp Infect 81: 1–14.
102. Wilcox M. Mooney L. Bendall R. Settle C. Fawley W. (2008) A case control study of community-associated Clostridium difficile infection. Antimicrob Chemother 62: 388–396.
103. Zar F. Bakkanagari S. Moorthi K. Davis M. (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45: 302–307.
104. Zilberberg M. Tillotson G. McDonald L. (2010) Clostridium difficile infections among hospitalized children, United States, 1997–2006. Emerg Infect Dis 16: 604–609.